Holly May
Corporate Officer/Principal bei BIOLINERX LTD.
Vermögen: - $ am 31.05.2024
Profil
Holly W.
May is currently the President-BioLineRx USA at BioLineRx Ltd.
She previously worked as the Vice President-Sales & Marketing at Swedish Orphan Biovitrum AB from 2018 to 2019.
Before that, she held positions as the Chief Commercial Officer at Avrobio, Inc., Vice President & Head-Commercial at Sobi, Inc., Vice President at Genzyme Israel Ltd., and Head-Marketing Operations at Sanofi-Aventis Israël Ltd.
Ms. May holds an MBA from the University of Akron and an undergraduate degree from the University of Miami.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
BIOLINERX LTD.
-.--% | 15.03.2024 | 0 ( -.--% ) | - $ | 31.05.2024 |
Aktive Positionen von Holly May
Unternehmen | Position | Beginn |
---|---|---|
BIOLINERX LTD. | Corporate Officer/Principal | 16.06.2022 |
Ehemalige bekannte Positionen von Holly May
Unternehmen | Position | Ende |
---|---|---|
SWEDISH ORPHAN BIOVITRUM AB | Vertrieb & Marketing | 01.08.2019 |
Sanofi-Aventis Israël Ltd. | Vertrieb & Marketing | - |
Genzyme Israel Ltd. | Corporate Officer/Principal | - |
Sobi, Inc. | Corporate Officer/Principal | - |
TECTONIC THERAPEUTIC, INC. | Corporate Officer/Principal | - |
Ausbildung von Holly May
University of Akron | Masters Business Admin |
University of Miami | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
BIOLINERX LTD. | Health Technology |
SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
Private Unternehmen | 4 |
---|---|
Avrobio, Inc.
Avrobio, Inc. BiotechnologyHealth Technology AVROBIO, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm's clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis. The company was founded by Geoff Mackay, Kim Warren, Christopher Mason, and Jeffrey Medin in 2015 and is headquartered in Watertown, MA. | Health Technology |
Sanofi-Aventis Israël Ltd. | |
Sobi, Inc. | |
Genzyme Israel Ltd. |